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1. Introduction 
The toxic action of snake venoms in humans 
bitten by snakes and after injection into experimental 
animals causes disturbances of brain, nerve, and 
muscle function (neurotoxic action); disturbances of 
heart function (cardiotoxic action); tissue damage 
(cytotoxic action); hematological disturbances 
(hemorrhage, anemia, changes in the coagulability 
of the blood and hemolysis); and finally shock [l] . 
However, the specific content of toxin components 
and enzymes in each venom, as well as the mechanism 
of action and the disturbances, vary from one species 
to another. The main pharmacological actions of 
Elapidae venoms are neurotoxic, cardiotoxic and 
cytotoxic actions [2]. In addition to neurotoxins, 
their venoms contain cardiotoxin (CTX) (=cytotoxin) 
as their major protein constituents [3] . 
Studies on the structure-activity relationships of 
biologically active components in the venom of 
Elapidae snake are being made in our laboratory. 
Recently, we fractionated the venom of Naja naja atra 
and isolated at least four CTXs, named CTX- 
analogues I, II, III and IV in the homogeneous states 
by polyacrylamide disc-gel electrophoresis [4]. The 
determination of the complete amino acid sequence 
aid a great help to demonstrate the functionally 
important amino acid residues. In previous papers, we 
reported the primary structures of CTX-analogues I 
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[5], II [6], and III [4], which was identical to CTX 
reported by Narita and Lee [7] . In this communication, 
we report the complete amino acid sequence of 
CTX-analogue IV. 
2. Materials and methods 
Lyophilized venom of Naja naja atra was pur- 
chased from Sigma Chemical Co., Ltd., USA. Bovine 
trypsin (three times recrystallized) was obtained from 
Worthington Biochemical Corp., USA. Sephadex G-25 
and G-50 were the products from Pharmacia Fine 
Chemicals, Sweden. Carboxymethyl(CM)-cellulose 
was obtained from Seikagaku Kogyo Co., Ltd., 
Japan. 
The venom dissolved in 1% acetic acid was applied 
to a column of Sephadex G-50 and eluted with 1% 
acetic acid as an eluent. Due to the molecular weight 
of CTXs (cytotoxins) isolated from the venom of 
Naja naja [3], the protein fraction with molecular 
weight of about 6 000-7 500 was freeze-dried and 
applied to a column of CM-cellulose equilibrated 
with 0.005 M sodium acetate buffer, Ph 5.8. The 
column was eluted with a gradient formed from 
the equilibration buffer in the mixing vessel and 
0.5 M sodium acetate, pH 6.5, in the reservoir. 
Each fraction was pooled, lyophilized, and then gel- 
filtered on a column of Sephadex G-25 to remove 
sodium acetate. The fourth fraction with cytotoxicity 
to Yoshida sarcoma cells was named CTX-analogue 
IV. To further purify the CTX-analogue IV fraction 
obtained, the sample dissolved in 0.2 M sodium 
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acetate buffer, pH 6.0, was applied to a column of 
CM-cellulose quilibrated with the same buffer. A 
gradient (from 0.2 M sodium acetate buffer, pH 
6.0, to 0.8 M sodium acetate buffer, pH 6.8) was 
then applied at the top of the column. The pooled 
protein fraction forming the major peak was lyophiliz- 
ed and the dried sample was gel-filtered to remove 
sodium acetate. Homogeneity was examined by poly- 
acrylamide disc-gel electrophoresis according to the 
method of Williams et al. [8]. Its LDso value in 
mice (NIH strain) by subcutaneous injection was 
determined by the method of Litchfield and Wilcoxon 
[9]. Cytotoxicity to Yoshida sarcoma cells was 
determined by the method of Braganca et al. [10] 
with some modifications. 
Preparation of the reduced and S-carboxymethy- 
lated(RCM)-CTX-analogue IV was performed as usual 
method described by Crestfield et al. [11]. Amino 
acid analyses of CTX-analogue IV, the fragments 
generated by cyanogen bromide cleavage and the 
tryptic peptides were carried out by standard method. 
Cyanogen bromide cleavage of the RCM-toxin was 
performed in 70% formic acid by the method of 
Gross and Witkop [12]. The resulting fragments were 
applied to a column of Sephadex G-50 equilibrated 
with 0.2% acetic acid and were eluted with the same 
elution medium. The degradative Edman procedure 
as modified by Iwanaga et al. [13] was adopted to 
determine the sequence of the RCM-toxin and the 
fragments CB-III generated by cyanogen bromide 
cleavage of the RCM-toxin. The phenylthiohydantoin 
amino acids were identified by thin layer chromato- 
graphy in several solvent systems [ 14,15]. The trypsin 
digestion of the fragments CB-I and CB-III was carried 
out at 37°C for 8 h. The digests were applied to a 
preparative high voltage paper electrophoresis u ing 
a solvent system of pyridine/acetic acid/water 1:10: 
289, by volume, pH 3.6, at 30-35 V/cm for 2 h. Guide 
Table 1 
Amino acid composition of cardiotoxin-analogue IV 
and fragments generated by CNBr cleavage 
Amino acid Cardiotoxin- CNBr fragments 
-analogue IV 
CB-I CB-II CB-III 
CM-Cysteine - 3.38 (3) 
Aspartic acid 7.93 (8) 2.24 (2) 
Threonine 2.61 (3) 1.00 (1) 
Serine 2.17 (2) 0 
Glutamic acid 0.12 (0) 0 
Proline 4.15 (4) 1.85 (2) 
Glycine 2.07 (2) 1.04 (1) 
Alanine 1.80 (2) 1.00 (1) 
Half-Cystine 7.20 (8) 0 
Valine 5.83 (8) 1.15 (1) 
Methionine 2.07 (2) 0 
Isoleucine 1.00 (1) 0 
Leucine 5.15 (6) 2.91 (3) 
Tyrosine 2.73 (3) 1.87 (2) 
Phenylalanine 1.63 (2) 1.27 (1) 
Tryptophan 0 0 
Lysine 6.93 (8) 5.95 (5) 
Histidine 0 0 
Homoserine - 0. 80 (1) 























Numbers in parentheses represent the values from the amino acid sequence. In 
cardiotoxin-analogue IV, the value of isoleucine was taken as 1.0, in CB-I and 
CB-III, the value of alanine was taken as 1.0, and in fragment CB-II, the value 
of phenylalanine was taken as 1.0. 
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strip (5 mm) was cut and stained with ninhydrin 
reagent. Each band was extracted with a solution 
of 0.1 M pyridine, adjusted to pH 5.0 with acetic 
acid. The purities of extracted peptides were examined 
by paper chromatography using a solvent system 
of (a) 1-butanol/acetic a id/pyridine/water 15: 3:10: 
12, by volum e, (b) 1-butanol/acetic a id/water 4:1:5, 
by volume, or (c) watersaturated phenol. When they 
did not show one spot, further purification was 
preparatively performed by paper chromatography 
using a solvent system described above. The peptide 
and the fragment numbers refer to the order of their 
location in the sequence starting from the amino- 
terminal end. 
3. Results and discussion 
CTX-analogue IV was obtained in a yield of 
about 8.1% from the crude venom. The LDso in 
mice by subcutaneous injection was estimated to be 
48 (42-53)  ttg/g body weight, and 50% lysis of 
Yoshida sarcoma cells (=cytotoxicity) was observed 
at a concentration of 13.5/zg protein/ml. Judging 
from the elution profile of the toxin on a Sephadex 
G-50 column, the amino acid composition, and the 
molecular weight of other known CTX-analogues, 
one molecule of CTX-analogue IV contains about 
60 amino acid residues: Asp 7.93, Thr.2.61, Ser 2.17, 
Glu 0.12, Pro 4.15, Gly 2.07, Ala 1.80, Half-Cys 
7.20, Val 5.83, Met 2.07, lie 1.00, Leu 5.15, Tyr 2.73, 
Phe 1.63, Lys 6.93, Arg 2.76. 
Direct Edman degradation of RCM-toxin revealed 
the first 29 amino acid sequence to be: H-Arg-Lys- 
Cys-Asn-Lys-Leu-Val-Pro-Leu-Phe-Tyr-Lys-Thr-Cys- 
-Pro-Ala-Gly-Lys-Asn-Leu-Cys-Tyr-Lys-Me t Phe-Met- 
-Val-Ser-Asn-. According to this sequence, two 
Table 2 
Amino acid composition of tryptic peptides of CB-I of cardiotoxin-ana/ogue IV 
Amino acid T-1 T-2 T-3 T-4 T-5 T-6 T-7 T-8 CB-I 
CM-Cysteine 1.00 (1) 1.13 (1) 1.19 (1) 3 
Aspar tic acid 1.10 (1) 1.13 (1) 2 
Threonine 0.91 (1) I 
Serine 0 
Glutamic acid 0 
Proline 1.0____0 (1) 1.43 (1) 0.95 (1) 2 
Glycine 1.11 (1) 1 
Alanine 1.05 (1) 1 
Half-Cysteine 0 
Valine 0.84 (1) 0.93 (1) 1 
Methionine 0 
Isoleucine 0 
Leucine 2.26 (2) 1.86 (2) 1.06 (1) 3 
Tyrosine 0.75 (1) 0.64 (1) 0.83 (1) 2 
Phenylalanine 0.75 (1) 0.71 (1) 1 
Tryptophan 0 
Lysine 1.0___0 (1) 1.0_0 (1) 1.0__0 (1) 1.00 (1) 1.00 (I) 1.0___0 (1) 5 
Histidine 0 
Homoserine 1.00 (1) 1 
Arginine 1.07 (1) I 
Total 2 3 4 3 7 6 5 1 
Yield (%) 20 18 14 23 10 24 28 25 
Solvent a (a) (a,c) (a) (a) (a) (a,c) (a) (a) 
In each column the values of the amino acids underlined were taken as 1.0. 
The numbers in parentheses represent the values from the amino acid sequences. 
a Solvent represents he solvent system used for the separation of tryptic peptides by paper chromatography (see Materials and 
methods). 
219 
Volume 70, number 1 FEBS LETTERS November 1976 
methionine residues were found in the central part 
of the toxin molecule. Then, the RCM-toxin was 
cleaved with cyanogen bromide. The resulting 
fragments were separated with a Sephadex G-50 
column using a 0.2% acetic acid as an eluent. The 
amino acid compositions of  the fragments obtained 
are given in the table 1. 
Using the carboxy-terminal fragment CB-III, from 
which homoserine was absent, stepwise Edman 
degradation was performed to demonstrate all of 
the amino acid sequence, viz: -Val-Ser-Asn-Leu-Thr- 
Val-Pro-Val-Lys-Arg-Gly-Cys-Ile-Asp-Val-Cys-Pro-Lys- 
Asn-Ser-Ala-Leu-Val-Lys-Tyr-Vat-Cys-Cys-Asn-Thr- 
Asp-Arg-Cys-Asn-OH. The central fragment CB-II 
which was eluted at the column volume in the gel 
filtration was determined to be phenylalanylhomo- 
serine. On the basis of the above results, the amino 
acid sequence of CTX-analogue IV was deduced to 
be CB-I-II-III. 
This sequence of  CTX-analogue IV was further 
ascertained by analyzing the peptides obtained by 
the trypsin digestion of the CB-I and CB-III. After 
the digestion of each fragment by trypsin, the 
resulting peptides were separated by a combination 
of high-voltage paper electrophoresis and paper 
chromatography. The amino acid compositions of the 
peptides were determined by amino acid analyses and 
are shown in tables 2 and 3. 
The complete amino acid sequence of CTX-analogue 
IV from the present study is now shown in fig. 1 and 
indicates that the molecular weight is 6 801. This 
value is almost he same as those of other CTX- 
analogues. 
There is a remarkable similarity between CTX- 
Table 3 
Amino acid composition of tryptic peptides of CB-III of cardiotoxin-analogue IV 
Amino acid T'-I T'-2 T'-3 T'-4 T'-5 T'-6 CB-III 
CM-Cysteine 1.89 (2) 1.98 (2) 0.97 (1) 5 
Aspartic acid 1.50 (1) 1.20 (1) 1.36 (1) 2.19 (2) 1.00 (1) 6 
Threonine 0.86 (1) 0.96 (1) 2 
Serine 1.30 (1) 1.30 (1) 2 
Glutamic acid 0 
Proline 1.30 (1) 1.24 (1) 2 
Glycine 1.11 (1) 1 
Alanine 1.19 (1) 1 
Half-Cysteine 0 
Valine 3.36 (3) 0.81 (1) 1.36 (1) 0.64 (1) 6 
Methionine 0 
lsoleucine 1.00 (1) 1 
Leucine 1.44 (1) 1.22 (1) 2 
Tyrosine 0.68 (1) 1 
Phenylalanine 0 
Tryptophan 0 
Lysine 1.00 (1) 1.00 (1) 1.00 (1) 3 
Histidine 0 
Homoserine 0 
Arginine 1.00 (1) 1.00 (1) 2 
Total 9 1 8 6 8 2 
Yield (%) 27 38 29 35 25 60 
Solvent a (a) (a) (b) (a) (b) (a) 
In each column the values of the amino acid underlined were taken as 1.0. 
The numbers in parentheses represent the values from the amino acid sequences. 
a Solvent represents he solvent system used for the separation of tryptic peptides by paper chromato- 
graphy (see Materials and methods). 
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1 -_._A_A----\_lQ\\--\ 
H-Arg-Lys-Cys-Asn-Lys-Leu-Val-Pro-Leu-Phe-Tyr-Lys-Thr-Cys-Pro- 
47 76 74 60 60 67 64 66 50 54 58 32 37 34 31 
+T-l-t-T-2+ c---T-3 ----_,e-T-4+ t------T-6 
t---------T-5 _____j 
4 CB-I 




31 26 16 17 22 18 18 10 15 15 13 
-e---T-7-+T-89 ,bd 27 !?6 80 
40 
Thr-~-Pro-~-~-Arg-&y-~-~-~-~-Cys-~-Lys-~- 
42 56 52 54 39 22 49 44 47 45 38 36 34 20 24 




21 22 21 21 13 19 17 16 16 11 10 11 3 7 5 
-T'-4-+-T'-5 -CT'-6+ 
Fig. 1. Amino acid sequence of cardiotoxin-analogue IV from formosan cobra venom (Nuju nuju QPQ). Horizontal arrows below 
amino acid residues denote the sequence of CNBr fragments derived from RCM-toxin and tryptic peptides. Right-handed arrows 
show that the sequence was elucidated by Edman degradation. T and T’ represent he peptides produced by tryptic digestion of 
fragments CBaI and CB-III, respectively. Numbers below amino acid residues how the yield (%) of phenylthiohydantoin amino 
acids estimated from the molar absorbance coefficient at 269 nm and based on the amounts of samples used in the Edman 
degradation. 
analogue II and CTX-analogue IV. CTX-analogue 
IV differs from CTX-analogue II only in the presence 
of arginine residue in place of leucine residue at 
position 1. CTX-Analogue IV is the first toxin found 
with an arginine residue at amino terminus of the 
toxin molecule among cardiotoxins, although there 
are some neurotoxins having an arginine residue in 
the position [16,17]. 
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